For example, elevated IL-6 has been incorporated into risk stratification protocols to identify patients who may benefit from early administration of immunomodulatory therapies such as tocilizumab, with several studies reporting reduced progression to respiratory failure and improved survival in high-risk patients [62]. Here, IL6 is linked to respiratory failure.